An autonomous AI medical device successfully managed 94% of urgent skin cancer referrals across two U.K. National Health Service hospital sites, discharging over a quarter of benign cases without dermatologist review. Over a 16-month study involving 8,391 patients, the system saved approximately 2,850 hours of clinician time—boosting clinical capacity by 62%—while achieving over 97% sensitivity for malignancy across all skin cancer types.
UK hospital study AI referral triage
- ▪In the U.K. hospital study, the AI device demonstrated sensitivity for malignancy exceeding 97% across all skin cancer types and achieved a specificity of 72.1%.
- ▪Researchers deployed the autonomous AI device in December 2024 and July 2025 at two National Health Service hospital sites in the United Kingdom, managing 8,391 patients.
- ▪The AI triage device safely discharged 31% and 25% of benign skin cancer cases without clinician review at the two U.K. hospital sites.
- ▪An autonomous artificial intelligence device successfully managed 94% of urgent suspected skin cancer referrals during a 16-month study conducted across two U.K. hospital sites.
Dermatology capacity and time savings
- ▪Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.
- ▪The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.
- ▪Researchers estimated that integrating the AI medical device resulted in a 62% increase in overall clinical capacity for dermatologists.
- ▪The implementation of the AI device saved approximately 2,850 hours of clinician time, equivalent to over 8,500 face-to-face dermatology consultations.
Swedish primary care trial of Dermalyser
- ▪Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.
- ▪In the Swedish primary care trial, the Dermalyser app achieved an overall area under the ROC curve of 0.960 with 95.2% sensitivity and 84.5% specificity for distinguishing melanoma.
Story comments
Loading comments…